AU744981B2 - Method of treating bronchitis with uridine triphosphates and related compounds - Google Patents

Method of treating bronchitis with uridine triphosphates and related compounds Download PDF

Info

Publication number
AU744981B2
AU744981B2 AU49866/97A AU4986697A AU744981B2 AU 744981 B2 AU744981 B2 AU 744981B2 AU 49866/97 A AU49866/97 A AU 49866/97A AU 4986697 A AU4986697 A AU 4986697A AU 744981 B2 AU744981 B2 AU 744981B2
Authority
AU
Australia
Prior art keywords
compound
formula
subject
double bond
clearance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU49866/97A
Other languages
English (en)
Other versions
AU4986697A (en
Inventor
Richard C. Boucher Jr.
Karla M. Jacobus
Janet L. Rideout
Christy L. Shaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Merck Sharp and Dohme LLC
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AU4986697A publication Critical patent/AU4986697A/en
Application granted granted Critical
Publication of AU744981B2 publication Critical patent/AU744981B2/en
Assigned to INSPIRE PHARMACEUTICALS, INC., UNIVERSITY OF NORTH CAROLINA, THE reassignment INSPIRE PHARMACEUTICALS, INC. Alteration of Name(s) in Register under S187 Assignors: INSPIRE PHARMACEUTICALS, INC.
Assigned to MERCK SHARP & DOHME CORP., UNIVERSITY OF NORTH CAROLINA, THE reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) in Register under S187 Assignors: INSPIRE PHARMACEUTICALS, INC., UNIVERSITY OF NORTH CAROLINA, THE
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU49866/97A 1996-11-07 1997-10-21 Method of treating bronchitis with uridine triphosphates and related compounds Expired AU744981B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/744367 1996-11-07
US08/744,367 US6159952A (en) 1996-11-07 1996-11-07 Method of treating bronchitis with uridine triphosphate and related compounds
PCT/US1997/018766 WO1998019685A1 (en) 1996-11-07 1997-10-21 Method of treating bronchitis with uridine triphosphates and related compounds

Publications (2)

Publication Number Publication Date
AU4986697A AU4986697A (en) 1998-05-29
AU744981B2 true AU744981B2 (en) 2002-03-07

Family

ID=24992452

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49866/97A Expired AU744981B2 (en) 1996-11-07 1997-10-21 Method of treating bronchitis with uridine triphosphates and related compounds

Country Status (14)

Country Link
US (1) US6159952A (enExample)
EP (1) EP0941099B1 (enExample)
JP (1) JP2001505553A (enExample)
KR (1) KR100518066B1 (enExample)
CN (1) CN1115152C (enExample)
AT (1) ATE249833T1 (enExample)
AU (1) AU744981B2 (enExample)
BR (1) BR9714312A (enExample)
CA (1) CA2271126C (enExample)
DE (1) DE69724991T2 (enExample)
ES (1) ES2207723T3 (enExample)
NO (1) NO992197L (enExample)
NZ (1) NZ335540A (enExample)
WO (1) WO1998019685A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
EP1012154B1 (en) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6251693B1 (en) 1998-07-30 2001-06-26 Micron Technology, Inc. Semiconductor processing methods and semiconductor defect detection methods
AR023088A1 (es) * 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
GB2394419B (en) 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
EP1750740A4 (en) * 2004-05-06 2009-06-10 Molichem Medicines Inc TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011016A1 (en) * 1990-12-22 1992-07-09 Fisons Plc Pharmaceutical composition containing uridine 5'-triphosphate for the treatment of cystic fibrosis
WO1994008593A1 (en) * 1991-06-19 1994-04-28 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU6176496A (en) * 1995-06-07 1996-12-30 University Of North Carolina At Chapel Hill, The Dinucleotides useful for the treatment of lung disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US3960840A (en) * 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DK0508687T3 (da) * 1991-04-06 1996-02-05 Astra Pharma Prod ATP-analoger
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011016A1 (en) * 1990-12-22 1992-07-09 Fisons Plc Pharmaceutical composition containing uridine 5'-triphosphate for the treatment of cystic fibrosis
WO1994008593A1 (en) * 1991-06-19 1994-04-28 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU6176496A (en) * 1995-06-07 1996-12-30 University Of North Carolina At Chapel Hill, The Dinucleotides useful for the treatment of lung disease

Also Published As

Publication number Publication date
DE69724991D1 (de) 2003-10-23
ATE249833T1 (de) 2003-10-15
CA2271126A1 (en) 1998-05-14
BR9714312A (pt) 2000-05-02
JP2001505553A (ja) 2001-04-24
CA2271126C (en) 2008-04-08
KR100518066B1 (ko) 2005-09-28
CN1115152C (zh) 2003-07-23
DE69724991T2 (de) 2004-11-11
CN1236318A (zh) 1999-11-24
US6159952A (en) 2000-12-12
ES2207723T3 (es) 2004-06-01
EP0941099A1 (en) 1999-09-15
NZ335540A (en) 2001-05-25
AU4986697A (en) 1998-05-29
WO1998019685A1 (en) 1998-05-14
KR20000053094A (ko) 2000-08-25
EP0941099B1 (en) 2003-09-17
NO992197L (no) 1999-07-05
NO992197D0 (no) 1999-05-05

Similar Documents

Publication Publication Date Title
AU744981B2 (en) Method of treating bronchitis with uridine triphosphates and related compounds
EP0831777B1 (en) Dinucleotides useful for the treatment of lung disease
US5876700A (en) Methods of hydrating lung mucous secretions with benzamil or phenamil
AU727790B2 (en) Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients
US6080762A (en) Pulmonary and nasal delivery of raloxifene
JP2001513568A (ja) 肺疾患を治療するためのウリジン５’−ジホスフェートとその類似体の使用
AU747350B2 (en) Novel pharmaceutical compositions of uridine triphosphate
MXPA99004283A (en) Method of treating bronchitis with uridine triphosphates and related compounds
HK1022263A (en) Method of treating bronchitis with uridine triphosphates and related compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NORTH CAROLINA, INSPIRE PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: INSPIRE PHARMACEUTICALS, INC.